前列地尔联合依达拉奉治疗急性缺血性脑卒中的疗效分析

目的研究前列地尔联合依达拉奉治疗急性缺血性脑卒中的临床疗效。方法 2016年6月~2019年6月期间住院的共128例急性缺血性脑卒中患者随机分为观察组和对照组。对照组采用依达拉奉治疗,观察组采用前列地尔和依达拉奉治疗,疗程共14 d,比较两组患者的临床疗效。结果两组患者治疗第14天的脑卒中量表评分和血清超敏C-反应蛋白水平均显著下降,观察组的下降程度明显大于对照组,差异有统计学意义(4.78±2.44)分vs.(7.54±2.38)分,P<0.05;(7.98±4.6)mg/L vs.(11.92±4.65)mg/L,P<0.05]。两组患者治疗后第90天的日常生活能力评分则显著增加,观察组的增加程度明显高于对照组,差异有统计学意义(70.04±6.28)分vs.(59.98±6.45)分,P<0.05]。两组药物不良反应无显著性差异(P>0.05)。结论前列地尔联合依达拉奉治疗急性缺血性脑卒中有效并安全。

Analysis of treatment effect of alprostadil combined with edaravone on acute ischemic stroke

Objective To study the clinical effect of alprostadil combined with edaravone on acute ischemic stroke.Methods From June 2016 to June 2019,128 patients with acute ischemic stroke were randomly divided into observation group and control group.The control group was treated with edaravone,while the observation group was treated with alprostadil and edaravone for 14 days.The clinical efficacy of the two groups was compared.Results The scores of stroke scale and the levels of serum hypersensitive C-reactive protein were significantly decreased in both groups on the 14th day of treatment.The scores of stroke scale and the hs-CRP in the observation group was significantly lower than that in the control group(4.78±2.44)vs.(7.54±2.38)scores,P<0.05;(7.98±4.6)vs.(11.92±4.65)mg/L,P<0.05].The score of ADL in the observation group was significantly higher than that of the control group on the 90th day after treatment,and the difference was statistically significant(70.04±6.28)vs.(59.98±6.45),P<0.05].There was no significant difference in adverse drug reactions between the two groups(P>0.05).Conclusion Alprostadil combined with edaravone is effective and safe in the treatment of acute ischemic stroke.